QC basics Flashcards

1
Q

UV looking for

A

wavelengths

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What do you compare TLC to?

A

a standard

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are you looking for in uniformity of mass

A

deviation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the key components of a HPLC?

A

Main High-Performance Liquid Chromatography (HPLC) Components. The HPLC system mainly consists of an infusion pump, a sampler, a chromatographic column, a detector, and a data recording and processing device. Among them, the infusion pump, the chromatographic column, and the detector are key components

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What types of issues would you expect from a HPLC and how would you identify them?

A

One of the most common peak problems in HPLC is peak splitting or broadening. This can be caused by a variety of factors, including column overload, poor column packing, or improper mobile phase composition. In some cases, peak splitting can also be caused by sample matrix effects or poor sample preparation techniques

One common error in HPLC is poor peak shape. This can be caused by a number of factors, including an improper choice of stationary phase, an incorrect flow rate, or a faulty column. To fix this issue, the first step is to identify the cause of the problem.

Variable peak heights, split peaks, and broad peaks can be caused by incompletely filled sample loops, incompatibility of the injection solvent with the mobile phase, or poor sample solubility. Whenever possible, dissolve and inject samples in mobile phase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How would you validation a HPLC system?

A

Change control, IQ, OQ, PQ, Method Validation.

Validation of HPLC method gives information about various stages and parameters like accuracy, precision, linearity, Limit of detection, Limit of quantification, specificity and robustness. Validation should be done as per regulatory guidelines such as ICH guidelines.

In case of an HPLC method, it is assured by complete separation of peak(s) of analyte(s) from other peaks originated from the sample matrix. Specificity evaluation was done by injecting separately 20 µl solution of standard, sample, placebo, and blank into the chromatographic system.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What do you understand by Dissolution (Type 1 and 2)?

A

basket type (apparatus I) and paddle type (apparatus II) are most commonly used for oral solid dosage forms but many different product types, from capsules to creams, can be testing using the apparatus defined in the USP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Can you describe a dissolution bath and the important aspects wrt to setup and key parameters?

A

Usually consists of 6 containers each containing a solvent and basket or paddle. The solvent should be set to a specific temperature (approx. 37) and be a specific volume (approx. 1000mL) and the paddle or basket should be set at a specific speed.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How would you calibrate a dissolution bath?

A

Change control, URS, IQ, OQ, PQ including: Rotation per minute by using Digital Tachometer, Vessel temperature calibration by Digital Thermometer, Paddle/ basket wobble test by using Wobble Centering Gauge, Distance between the bottom edge of basket/paddle to the lowest inner surface of vessel by using Depth Gauge.
The study should include a measurement of the speed of the shaft rotation for each vessel contained within the dissolution apparatus. Speed should be measured using a photo tachometer for 30 minutes or the time specified in the individual monograph, whichever is greater.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What reference tablets do you use for dissolution testing?

A

Prednisone Tablets with the Paddle Method and Salicylic Acid Tablets with the Basket Method

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

in dissolution what is the meaning of the Q value?

A

Q represents the targeted amount of active substance, expressed as a percentage of the label claim, which should be dissolved within a certain time. The ‘Q value’ should be seen as a “reference value” to which the dissolution results are compared.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Wrt sample methods i.e. swabs and rinse waters what are their respective pros and cons?

A

Swabbing and rinsing are the two most common techniques used for sampling of cleaned surfaces). Swabbing is a direct surface sampling method, while rinsing is an indirect method. In practice, physical access to surfaces and parts of equipment to be cleaned tends to drive the choice of sampling method.

Two advantages of using rinse samples are that a larger surface area may be sampled, and inaccessible systems or ones that cannot be routinely disassembled can be sampled and evaluated

A disadvantage of rinse samples is that the residue or contaminant may not be soluble or may be physically occluded in the equipment

The swab test offers the advantage that sampling can be carried out directly at the critical points and even sparingly soluble residues can be collected. The disadvantages are the high demands on analytical method development and the problem of reproducibility.

The disadvantages of swab tests are mainly that the testing protocol needs to be more rigorous, in order to get consistent results. It is hard to know exactly what surface has been sampled (the contact between the swab tip and the surface depends on the swab angle), and how much pressure was applied.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Validation of an analytical method. What standard would you use and where would you find it. What are the factors to be validated.

A

Follow ICH Q2 guidance. Factors could include accuracy and precision, specificity, LOD, LOQ, Range, Robustness and repeatability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How would you deal with an OOS analytical result?

A

Is it a true result? Follow MHRA guidance on OOS investigation - phase 1a, phase 1b, hypothesis testing, Phase 2, deviation investigation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is a system suitability test and what is it looking for?

A

“System Suitability Tests are an integral part of gas and liquid chromatographic methods. They are used to verify that the resolution and reproducibility of the chromato- graphic system are adequate for the analysis to be done.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Where would you find information on system suitability tests?

A

Pharmacopeia and ICH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Explain the BP uniformity of weight test?

A

Weigh individually 20 units taken at random or, for single-dose preparations presented in individual containers, the contents of 20 units, and determine the average mass - not more than 2 deviate from the average weight by a percentage greater than that specified

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Explain the BP content of uniformity test?

A

The test for uniformity of content of single-dose preparations is based on the assay of the individual contents of active ingredient of a number of single-dose units to determine whether the individual contents are within limits set with reference to the average content of the sample.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Tell me about antibiotic assays e.g. pros and cons of bioassays as opposed to HPLC?

A

An antibiotic assay tests enable the serum concentrations of certain antibiotics to be monitored. This helps to ensure adequate dosing for efficacy, and to avoid risks associated with potentially toxic levels.

Two kinds of assays are usually referred: dilution and diffusion. In the former, the antibiotic is presented to the test organism at one concentration. The concentration is uniform throughout the medium. The medium may be liquid as in tube methods or solidified by agar as in a plate dilution method.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is Bio-assay.

A

A bioassay is an analytical method to determine the potency or effect of a substance by its effect on living animals or plants, or on living cells or tissues.

Bioassays provide valuable information concerning the potency of biological products. This is essential for evaluating batch-to-batch consistency and stability. Bioassay data are crucial at all stages in the development of biological products, from early research work to final quality control of finished products
Advantages: Quick and simple with more precision than a matching assay. There is a possibility of using certain statistical procedures although not with much confidence. Disadvantages: still an inherent lack of precision, no accuracy, need for specific organisms and potential limitations in detecting certain contaminants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Parametric release. What does this mean?

A

Parametric release is a system of release that gives the assurance that terminally sterilised product is of the intended quality based on information collected during the manufacturing process and on the compliance with specific GMP requirements related to Parametric Release

There is no performance of a sterility test, so no waiting for results and no additional delays due to investigations of common “false” sterility test positive results. Another benefit may be financial savings from the absence of expenses related to sterility testing and product holding.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Sterilisation out of specification, test product, sterility test OK what then?

A

Batch is still in the bin, if we have a failed sterilisation cycle the batch cannot be released - this will be one of the release checks therefore no impact to product on the market

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What information would you expect on a CofA and CofMc?

A

A Certificate of Analysis (COA) is a document that communicates the results of a scientific test done on a product such as food or drugs. The COA also lists the chemicals used in the product’s manufacturing and testing and is created to ensure all important regulations are met and complied with.
-the name and address of the laboratory issuing the CoA;
–the identification number of the CoA and on each page an identification, the page number and the total number of pages to ensure that every page is recognized as a part of the certificate;
–the name, address and contact person representing the originator of the request for analysis;
–the number assigned to the sample by the laboratory during registration upon receipt;
–the date on which the sample was received in the laboratory and the quantity of sample (number of units or packages);
–the name, description (for example, active ingredient, dosage form, strength, package size in the case of FPPs; grade in the case of starting materials; type and material of the primary packaging), batch number (used by the original manufacturer and repacker or trader) of the sample for which the certificate is issued, the expiry date (or retest date, where applicable) and date of manufacture (if available);
–the name and address of the original manufacturer; in addition, if supplied by repackers or traders, the certificate should show the name and address of the repacker or trader;
–specifications for testing and a reference to the test procedure(s) used, including the acceptance criteria (limits);
–the results of all tests performed on the sample for which the certificate is issued (in numerical form, where applicable) and a comparison with the established acceptance criteria (limits); results of tests performed by subcontractors should be identified as such;
–any comments, observations or information on specific test conditions, where these are necessary for the interpretation of the results;
–a conclusion as to whether or not the sample was found to be within the limits of the specification;
–the date and signature of the head of the laboratory or other authorized person approving the certificate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What statistics do you use in comparing 2 sets of results from two separate laboratories?

A

A t-test is a statistical hypothesis test used to test whether the difference between the response of two groups is statistically significant or not. It is any statistical hypothesis test in which the test statistic follows a Student’s t-distribution under the null hypothesis.

T-tests are used when the data sets follow a normal distribution

(1) one-sample t-test; (2) two-sample t-test; and (3) two-sample paired t-test.

The Student’s t test is used to compare the means between two groups, whereas ANOVA is used to compare the means among three or more groups.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Describe the contents of a typical monograph.

A

Monographs articulate the quality expectations for a medicine including for its identity, strength, purity, and performance. They also describe the tests to validate that a medicine and its ingredients meet these criteria.

A pharmacopeial monograph provides detailed parameters that are used to determine whether a medicine meets key quality attributes and can be marketed legally in any given country

a monograph contains detailed instructions for identification, purity tests and other specific tests to limit the amount of undesirable impurities, all of which may be used to verify common requirements by manufacturers and formulators concerned with the quality of their ingredients and products.
Contents: Action and use, definition, content of drug, Identification, Tests (e.g. dissolution - test conditions, procedure, determination of content, related substances, test conditions etc), Assay (method, conditions, system suitability, determination of content), labelling, impurities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What is the difference between British Pharmacopoeia and European Pharmacopoeia?

A

The BP is the only comprehensive collection of authoritative official standards for UK pharmaceutical substances and medicinal products. It contains all texts and monographs of the European Pharmacopoeia (signposted with a chaplet of stars), as well as the national standards developed by the BP.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What is meant by the limit of detection and limit of quantification?

A

Limit of Blank (LoB), Limit of Detection (LoD), and Limit of Quantitation (LoQ) are terms used to describe the smallest concentration of a measurand that can be reliably measured by an analytical procedure.

28
Q

What is accuracy & precision?

A

Accuracy and precision are two measures of observational error. Accuracy is how close a given set of measurements are to their true value, while precision is how close the measurements are to each other.

29
Q

What would you look for in an analytical validation protocol?

A

Follow ICH Q2:
The most widely applied typical validation characteristics for various types of tests are accuracy, precision (repeatability and intermediate precision), specificity, detection limit, quantitation limit, linearity, range, and robustness

30
Q

What tests will you find on your products finished product specification?

A

Identification and assay of antimicrobial agents or antioxidant preservatives (with acceptance limits);
purity tests (if necessary, the investigation of breakdown products, residual solvents or other process related impurities, microbial contamination);
pharmaceutical tests (e.g. dissolution)

31
Q

You are having a new laboratory what do you need to consider for transfer and validation?

A

Follow guidance in EU GMP Chapter 7 - outsourced activities, EU GMP Annex 15 - validation and qualification and ICH Q2 method validation

32
Q

Sample receipt

A

On receipt, the sample should be checked for:
* Integrity and good condition
* Key information
➢ Identity
➢ Lot number
➢ Part number?
➢ Container number (x of y)
➢ Sample volume or weight
➢ Date
➢ Sampler

33
Q

System suitability

A

Confirmatory test(s) procedures and parameters to ensure that the system (equipment, electronics, and
analytical operations and controls to be analysed) will function correctly as an integrated system at the
time of use. The system suitability acceptance criteria applied to standards controls and samples,
such as peak tailing, precision and resolution acceptance criteria, may be required as applicable.

Carried out each time the analysis is performed to confirm that the analysis is acceptable on that occasion
* Well established approach for chromatographic methods which is easily applied to other separative techniques
* Commonly used in all types of analytical methods, not just separative

34
Q

Systematic error

A
  • The same influence affects the result for each of the repeated measurements (but you may not be able to tell)
  • In this case, you learn nothing extra just by repeating measurements
  • Other methods are needed to estimate uncertainties due to systematic effects, e.g. different measurements, or calculations

Have a definite value
* Have an assignable cause
* Are of the same magnitude for replicate measurements made in the same way
* Lead to bias in the measurement technique

35
Q

Random error

A
  • Repeating the measurement gives a randomly different result
  • If so, the more measurements you make, and then average, the better estimate you generally can expect to get

Caused by the many uncontrollable variables that are an inevitable part of every physical or chemical measurement
* Many contributors, but cannot be identified or measured – Most are so small they cannot be detected individually
* Accumulated effect of individuals causes replicate measurements to fluctuate around the mean of the set

36
Q

Method Performance Characteristics (Referred to as ‘Validation’ Characteristics in ICH Q2)

A
  • Specificity
    ‘Specificity is the ability to assess unequivocally the analyte in the presence of components which may be
    expected to be present. Typically these might include impurities, degradants, matrix, etc.’
  • Accuracy
    ‘The accuracy of an analytical procedure expresses the closeness of agreement between the value which is
    accepted either as a conventional true value or an accepted reference value and the value found. This is
    sometimes termed trueness.’
  • Precision
    ‘The precision of an analytical procedure expresses the closeness of agreement (degree of scatter) between a
    series of measurements obtained from multiple sampling of the same homogeneous sample under the
    prescribed conditions.
    The precision of an analytical procedure is usually expressed as the variance, standard deviation or
    coefficient of variation of a series of measurements.’
    • Repeatability
      ‘Expresses the precision under the same operating conditions over a short interval of time. Repeatability is
      also termed intra-assay precision.’
    • Intermediate precision
      ‘Intermediate precision expresses within-laboratories variations: different days, different analysts, different
      equipment, etc.’
    • Reproducibility
      ‘Reproducibility expresses the precision between laboratories (collaborative studies, usually applied to
      standardization of methodology).’
  • Detection limit
    ‘The detection limit of an individual analytical procedure is the lowest amount of analyte in a sample which can
    be detected but not necessarily quantitated as an exact value.’
    • Quantitation limit
      ‘The quantitation limit of an individual analytical procedure is the lowest amount of analyte in a sample
      which can be quantitatively determined with suitable precision and accuracy. The quantitation limit is a
      parameter of quantitative assays for low levels of compounds in sample matrices, and is used particularly
      for the determination of impurities and/or degradation products.’
  • Linearity
    ‘The linearity of an analytical procedure is its ability (within a given range) to obtain test results which are
    directly proportional to the concentration (amount) of analyte in the sample.’
  • Range
    ‘The range of an analytical procedure is the interval between the upper and lower concentration (amounts)
    of analyte in the sample (including these concentrations) for which it has been demonstrated
    that the analytical procedure has a suitable level of precision, accuracy and linearity.’
  • Robustness
    ‘The robustness of an analytical procedure is a measure of its capacity to remain unaffected by small, but
    deliberate variations in method parameters and provides an indication of its reliability during normal
    usage.’
37
Q

OOS re-measurement

A

Hypotheses regarding possible causes should be tested
– E.g. dilution error, instrument error, bubble in detector, etc.
* Examine/re-measure retained solutions as part of investigation
– E.g. re-injection, re-dilution or re-extraction
– This is NOT re-testing

38
Q

OOS - averaging replicates

A

If tests consist of replicates to arrive at result (e.g. replicate HPLC injections) the result from the
average response is considered one test and one reportable result.
 Need acceptance limits for variability
 If variability limits not met, do NOT use results
 Can specify a series of complete tests as replicates in the method
 Same need for variability acceptance limits
The FDA guidance then contradicts itself when it goes on to say: if a test has replicates to arrive at
result with:
 Individual replicate(s) OOS
 Average within specification
 All within known variability
The result should be treated as OOS as the true value may be OOS. This conflicts with the guidance
give earlier in the document that it is the reportable result that has to comply with the specification,
if this is what is registered.

39
Q

OOS outlier tests

A

Outlier testing is a statistical procedure for identifying extreme values within a data set. The usual
tests are Dixon’s Test or Cochran’s Test. The OOS SOP should include the specific statistical tests to
be used, with the relevant parameters specified. The SOP should specify the minimum number of
results required to obtain a statistically significant assessment from the specified test.
For validated chemical tests an outlier test is only a statistical analysis of the data. It will identify
statistical outliers but will not identify the cause of an extreme datum point, so should not be used
to invalidate the data. The investigation must attempt to identify why the point is an outlier.
For Biological Assays, an outlier test may be an appropriate means of testing for extreme values, but
be aware that arbitrary rejection or retention of an aberrant extreme value can be a serious source
of bias, and the procedure should be used sparingly.
Outlier tests should not be used for content uniformity or dissolution tests; rather the pharmacopeia
process should be followed.

40
Q

OOS inappropriate averaging

A

Averaging has the disadvantage of hiding variability amongst individual test results. Averaging is
therefore inappropriate for blend uniformity results or for content uniformity results.
Individual test results should be reported as separate values, unless averaging is specified by test
method.
It is acceptable to report other statistical metrics if required by test method, e.g. standard deviation
in Content Uniformity.
The FDA guidance states that “In OOS investigations you should NOT average original and re‐test/resample
results”. This statement is not always in accordance with statistical thinking. If the original
result is shown to be a statistical outlier when compared to the re‐tests, then the FDA statement is
correct. However, if the original result is not an outlier then the original result and the re‐tests
should be averaged to obtain the best estimate of the true result. It is recommended that as well as
calculating the mean of the results, you should also calculate the 95% confidence interval and only
consider releasing the batch if this confidence interval is within your specification limits.

41
Q

OOS batch disposition

A

Batch Disposition Following a Suspect Result
If a laboratory error is proven, the atypical result is invalid and you should base the final batch
disposition on results obtained by the repeat testing.
If a manufacturing error is proven, you should base the final batch disposition on the basis of the
original result. If the atypical result was OOS you must reject the lot, identify the cause of failure and
determine the impact on other lots.
If investigation is inconclusive and any re‐test results were also OOS, then you should reject the lot
and continue the investigation to find the cause (as above).
If investigation is inconclusive and all re‐tests meet specification, the lot may be releasable, if:
 No production aberrations or unusual variations
 Process and product history show process is robust
 The re‐test results are all within known variability for method
 (NSF/MHRA guidance is that you should also only consider releasing the batch if the 95% confidence interval is within your specification limits)
 All other results from lot (e.g. in‐process, content uniformity, dissolution) are consistent with re‐test results

42
Q

OOS stability failures

A

These are potentially even more serious than an OOS result on the release testing of a batch as
ongoing stability testing supports ALL lots of a product currently on the market. Hence, a failure
potentially impacts ALL lots of that product currently on the market.
You must immediately investigate OOS and OOT stability results. If the product is on the US market
the FDA must be alerted within 3 days of confirmation of a stability failure.
It is essential to ensure that the quantity placed on store at the start of the study is sufficient to
perform re‐testing (minimum of 5) on least two occasions during the study.
When performing re‐testing of an OOS or OOT stability result it adds more value to add additional
time points to the study rather than to performing all of the re‐tests at a single time point.

43
Q

The Top 10 OOS Behaviours

A
  1. Analytical results are routinely trended in order to identify out‐of‐trend (OOT) and other
    atypical results; using control charts for release test results and regression analysis for
    stability results.
  2. All results are calculated and checked against the applicable specification and the
    appropriate control chart or regression line before being reported.
  3. All laboratory glassware, instrumentation, etc. is retained in the state it was used for the
    analysis until the results have been checked and deemed fit to report.
  4. When an out‐of‐specification (OOS), OOT or atypical result is identified this is immediately
    alerted to appropriate supervisory staff and a laboratory investigation is initiated.
    Checklists may be used for routine analysis or instrumentation to act as aide‐mémoires and
    to assist with documenting laboratory investigations.
  5. Re‐measurement of previously prepared solutions, as part of the laboratory investigation, is
    only permitted using approved protocols that specify the purpose of the re‐measurement.
  6. Re‐testing (i.e. further analysis of the sample that was originally submitted to the laboratory)
    is only permitted after completion of both laboratory and production investigations and they
    have been assessed as being inconclusive.
  7. Re‐sampling (i.e. the collection of additional samples from a batch) requires that the
    samples be collected using the same sampling procedure as was used to obtain the original
    sample and is only permitted where there is evidence that the original sample was not taken
    correctly or was subsequently compromised.
  8. A minimum of 5 re‐test or re‐sample analyses are performed.
  9. Re‐test/re‐sample results should be statistically compared to the original result.
    If the OOS/OOT/atypical result is an outlier it should not be averaged with re‐test/re‐sample
    results and if it is not an outlier then it should be. As well as calculating the appropriate
    mean the 95% confidence interval of the mean should be calculated.
  10. If the OOS/OOT/atypical result investigation is inconclusive and all re‐test/re‐sample results
    meet specification, the lot may be releasable, if:
    a. There are no production aberrations or unusual variations,
    b. The process and product history show that the process is robust,
    c. The re‐test/re‐sample results are all within known variability for method,
    d. The whole of the 95% confidence interval of the overall mean is within specification
    limits,
    e. All other results from lot (e.g. in‐process, content uniformity, dissolution) are
    consistent with the re‐test/re‐sample results,
    f. Other factors such as stability and the use of the product are considered.
44
Q

Chirality

A

Occurs where a carbon atom has four different groups attached to it Mirror image = optical isomer

45
Q

Optical rotation

A

Like refractive index – sensitive to wavelength and temperature
* Determined – using polarimeter sodium D line as light source

46
Q

Applications of Spectroscopy in Pharmaceutical Analysis

A

The use of spectroscopic techniques is widespread in pharmaceutical applications. Indeed as it is the
most commonly used detection principle in HPLC and related physical separation techniques, an
understanding of the nature of the spectroscopic data generated is of fundamental importance to
pharmaceutical analysis. Many of these techniques are discussed in more detail in later lectures.
For the present it is sufficient to note some of the main application areas in the following table.

Application Area Spectroscopic Tool Box
Raw materials
 Identification UV, Near IR, IR, Refractometry
 Assay UV, Visible, Near IR, IR
 Metallic impurities Atomic spectroscopies; absorption, emission, fluorescence, ICP‐MS
 Physical properties Near IR, Refractometry, Optical rotation
Intermediates and finished products
 Identification UV, Near IR, IR
 Assay UV, Visible, Near IR, IR
 Process control UV, Visible, Near IR, IR
Packaging materials UV Visible, Near IR, IR and atomic spectroscopies
This list is by no means exhaustive but serves to give an indication of the broad view of spectroscopic
importance in pharmaceutical analysis.

47
Q

Electrophoresis

A

Motion of dispersed particles relative to a fluid under the influence of a spatially uniform electric field
* Electrophoresis is a general term that describes the migration and separation of charged particles
(ions) under the influence of an electric field
* An electrophoretic system consists of two electrodes of opposite charge (anode, cathode), connected by a conducting medium called an electrolyte

Gel electrophoresis
– SDS-PAGE
* Separates based on size
* May be combined with a antibody binding method such as in Western blotting
– Isoelectric Focussing
* Separates based on charge in a pH gradient
* Capillary electrophoresis

48
Q

Specific analytical methods

A

HPLC
Near Infra-red spectroscopy
Atomic absorption
Capillary electrophoresis
TLC

49
Q

None specific analytical methods

A

TOC
pH
Titration
Conductivity
Gravimetry
UV spectrophotometry

50
Q

QC purpose

A

Part of GMP concerned with sampling, specifications and testing
Ensure materials not released for use until quality checked
Results used to support batch release

Testing Types
Physical – pH, Moisture
Chemical – Assay, Impurities
Microbiological

Release data should be trended using Control Charts

51
Q

Sampling:

A

Samples must be representative of batch
Performed in accord. with defined sampling plan
Sample size determined statistically:
Packaging materials: ISO2859
Starting materials: WHO sampling guidance (n/p/r plan)
QRA for reduced testing of sampling materials

52
Q

Reference Standards:

A

Material of known purity, in-house or pharmacopoeial
Must have procedure for receipt, storage and use of reference standards

53
Q

Dissolution (OSD - 4 apparatus in Ph. Eur 2.9.3):

A

Mimics product dissolving in body
Dissolution media typically 0.1M HCl/phosphate buffer
Dissolution apparatus (basket/paddle) used depends on product nature:
Conventional OSD Apparatus 1&2 (b/p)
Prolonged release Apparatus 4 (flow thro cell – Inovelon)
CPPs: temp, time, speed, paddle position, media pH
Typically analysed by HPLC or UV
Multi-stage testing, can go to S3

54
Q

HPLC Chromatographic Parameters:

A

Column – stationary phase: Chemistry/Packaging materials/Dimensions
Flow Rate
Detector Settings
Mobile Phase – liquid phase: Solvents/Composition/Gradient/pH
Temperature
Injection volume

HPLC Detector Types:
UV/VIS: Fixed Wavelength
Photo Diode Array: Entire Spectrum
Mass Spectrometer

55
Q

HPLC System Suitability Tests (SST)

A

Column Efficiency (theoretical plate count) - N
USP and Pharm.Eur. have different calculations.
N is useful for monitoring column performance. N will decrease over time as the column degrades, useful for knowing when to change column or highlighting issues with the column.
Resolution
Measure of time (distance) between eluting peaks.
Peaks must be suitably resolved so they can be properly quantified.
Tailing factor (peak asymmetry)
Gives information on peak shape.
A result of <1 indicates fronting.
A result of >1 indicates tailing.
Quantitative Performance
RSD less than 2% for 5 injections of the same standard
Standard Check
Check using a separately (S2) prepared (weighed and diluted),
standard, against the standard used in the quantitative check (S1)
Retention Time/Relative Retention Time
Impurities: LOQ

56
Q

Typical SST (Assay method):

A

Blank
5 x S1 injections
1 x S2 injections

SST should ideally be checked to ensure it meets criteria before sample injections are run.

After initial SST, standards are used to bracket samples through out the run, the number of samples permitted between each standard will be documented in the test method.
Example sequence
SST
S1
Sample
Sample
S1
Sample
Sample
S1
etc

Test Method will detail which injection(s) in the SST the column efficiency, resolution, tailing factor should be take from to compare against criteria in test method.
However all peaks should be assessed against the criteria to indicate issues with the column or system during the run

57
Q

Stability testing

A

Purpose:
Set shelf life (linear regression)
Demonstrate API and FP will meet spec over shelf life
- Stability Testing Types:
New registrations
Routine manufacture (supports product in market)
Changes

New Product – Stability Testing Frequency
Minimum 3 batches
1st year: Test every 3 months
2nd year: Test every 6 months
Subsequent years: Test annually
Ongoing Stability Monitoring
1 batch a year of every pack type

Other Points:
Study starts day product put into chamber
Can use release testing as T0 if study started within 30 days of release testing
Establish ‘windows’ for pulling/testing samples
Can apply bracketing & matrixing
Stability data must be TRENDED (regression/control charts)
Confirmed OOS/sig. negative trends report to NCA
Stability tests & specs may be different to release tests
May have freeze thaw cycling/thermal cycling to support excursions in shipment/storage

58
Q

Stability indicating tests

A

Assay
Related Substances
Dissolution
Preservative content
Microbiology
pH
Viscosity
Appearance
Moisture
PET

59
Q

Q1E – Extrapolation of Shelf Life:

A

Where long term/accel. data shows no change can propose extrapolation of shelf life
Can be up to twice, but no more than 12 months beyond period covered by long term data

60
Q

Stability Guidance:

A

ICH Q1
ICH Q5C (Bio)
Q1A: New Drug Substances and Products (core stability data)
Q1B: Photostability Testing
Q1C: New Dosage Forms
Q1D: Bracketing and Matrixing
Q1E: Evaluation of Stability Data

61
Q

Stability Chambers:

A

Qualified and calibrated
Temperature Mapping
Temperature and RH monitored, alarm if out of conditions, assess excursion
Usage log, book samples in and out

62
Q

Mean Kinetic Temperature (MKT):

A

Assess impact of temp. variations, if within tolerances impact not sig
Temp. held over defined time period gives same thermal challenge as higher/lower temp for an equivalent defined period
ICH Q1

63
Q

OOS / OOT process

A

Phase 1a: To determine if there’s a clear obvious errors due to external circumstances e.g. power failure
If no assignable cause noted, move to Phase 1b

Phase 1b: Initial Investigation by the analyst and supervisor using lab investigation checklist.
Once checklist completed, re-measurement (check test) under documented hypothesis plan can start. Results only to support the investigation testing.
Initial hypothesis testing can include the original working stock solutions but should not include another preparation from the original sample.
If no assignable cause noted, move to Phase 2

Phase 2: Prior to further testing a manufacturing investigation should be started to determine whether there was a possible manufacturing root cause.
Further hypothesis testing if required.
Investigational testing can’t replace an original suspect analytical results. Only used to confirm or discount a probable cause.
No assignable cause identified during the manufacturing investigation or lab investigation, retesting may be considered.
Retesting, performed on the original sample not a different sample.
Can be a 2nd aliquot from the same sample.
If insufficient original sample remains to perform all further testing then the procedure for obtaining a resample must be discussed and agreed by QA. Obtaining the resample must be recorded in lab investigation.
The decision to retest should be based on sound scientific judgement.
Test plan must be approved before retesting occurs.
The minimum number of retests should be documented within the procedure and be based upon scientifically sound principles. The number of retests should be statistically valid (5, 7, or 9.)
Re-sampling:
The exception
Only when original sample exhausted, or original sample the root cause

Phase 2 cont:
Outlier test:
Statistical analysis for Outlier test results can be as part of the investigation.
it cannot be used to justify the rejection of data.
95% Confidence Interval level that the result is within specification.

Phase 3: If the batch is rejected there still needs to be an investigation. To determine if other batches or products are affected and to identification and implementation of corrective and preventative action.
Once a batch has been rejected there is no limit to further testing to determine the cause of failure, so that corrective action can be taken.
The decision to reject cannot be reversed as a result of further testing.
The impact of OOS result on other batches, on going stability studies, validated processes and testing procedures must be determined and be documented in the conclusion, along with CAPAs.
Conclusion:
No lab/calculation errors identified in Phase I and II  no scientific basis for invalidating initial OOS results in favour of passing retest results.
All test results, both passing & suspect, reported (in all QC documents and CoAs) and all data considered in batch release decisions.
If the investigation determines that the initial sampling method issue, a new accurate sampling method must be developed, documented, and reviewed and approved by QA. Consideration given to other lots sampled by the same method.
An initial OOS result does not necessarily mean the subject batch fails and must be rejected. The OOS result should be investigated, and the findings of the investigation, including retest results, should be interpreted to evaluate the batch and reach a decision regarding release or rejection which should be fully documented.
A confirmed OOS indicates the batch doesn’t meet specs  result in batch rejection. Other lots should be reviewed to assess impact.

64
Q

Micro OOS

A

Micro Investigation:
Difficult as results 1-2 weeks after analysis performed
Micro contamination will not be homogenous  sampling considerations
Consider organism type, organism source, media, supporting EM data, cleaning etc.

65
Q

Stability OOS

A

Stability Investigation:
Stability OOS/OOT investigated ASAP
OOT  stat. analysis to predict if OOS over shelf-life
Potential impact on product on market
NCA informed of confirmed OOS  recall potential